Published in Journal of Neurology Neurosurgery & Psychiatry · View the paper (DOI)
Researchers estimate that 32% of memory clinic attendees and 14% of specialist cognitive service patients are eligible for disease-modifying therapies. Biomarker testing is crucial to identify suitable patients, but only a minority have undergone tests.
Coverage from 2 institutions